Open-labelled Study to Evaluate the Effect of SE5-OH Tablets on Healthy Women With Menopausal Symptoms
NCT ID: NCT06398236
Last Updated: 2025-07-08
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
170 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-03-17
Study Completion Date
2024-10-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Multicentre, exploratory, prospective, open-labelled study to evaluate the efficacy of SE5-OH tablets on menopausal symptoms in healthy women experiencing menopausal symptoms after 12 weeks of administration.
The study will be performed in 10 hospitals (private and public) located in Spain. Recruitment period of 6 months will be defined in order to include up to 300 healthy volunteers from different national hospitals and clinics.
The study will be performed in 10 hospitals (private and public) located in Spain. Recruitment period of 6 months will be defined in order to include up to 300 healthy volunteers from different national hospitals and clinics.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Exploratory Investigation of Dietary Supplementation and the Effect on Common Symptoms of Perimenopause and Menopause
NCT05617287
Menopause
Menopause Related Conditions
Perimenopausal Disorder
COMPLETED
NA
Evaluate the Effect of Omega-3 vs Soy Isoflavones in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms
NCT02195609
Menopause
Hot Flashes
COMPLETED
PHASE4
Impact of Funcional Exercise and Supplementation in Perimenopausal Women's Health
NCT07251296
Perimenopause
Aging
RECRUITING
NA
The Menopause After Cancer Study
NCT04766229
Menopause
Cancer
Insomnia
COMPLETED
PHASE2
Effects of a New Botanical Extracts Combination on Quality of Life in Menopausal Spanish Women
NCT04381026
Menopause
Dietary Supplements
Quality of Life
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Multicentre, exploratory, prospective, open-labelled, non-controlled study to evaluate the efficacy of SE5-OH tablets for menopausal symptoms reduction. SE5-OH tablets are a food supplement containing active S-equol. The daily dose of S-equol is 10 mg in the form of 4 tablets of SE5-OH tablets.
The study will be performed in 10 hospitals (private and public) located in Spain to include up to 300 subjects in 6 months of recruitment period.
Investigators will review the medical history from healthy women with moderate to severe menopausal symptoms who are visiting the participating site, investigators will ensure that each candidate meets all the inclusion criteria and none of exclusion criteria. Suitable participants will be informed during the visit about the nature of the investigational study by receiving first information about the investigational product (food supplement) and invited to participate later when all questions have been addressed. A 14 days' period of reflexion is possible for every participant in accordance with Good Clinical Practice.
The procedures involved will be explained in detail and written consent must be obtained with subject and investigators signature before subject participation. The total duration of each participant in the study will be 16 weeks (12 weeks treatment + 4 weeks follow up). The participation in the study is completely voluntary.
The study consists of 4 visits: 3 visits until the end of treatment (EoT) with 1 follow up/end of study visit (FU/EoS) after treatment completion.
SE5-OH tablets will be administrated in tablets (4 per day) by daily oral intake until the day before the end of treatment date (week 12). Non-administrated SE5-OH tablets and VMS diary competition will be verified during the study in the corresponding visits until the EoS (visit 4).
The study will be performed in 10 hospitals (private and public) located in Spain to include up to 300 subjects in 6 months of recruitment period.
Investigators will review the medical history from healthy women with moderate to severe menopausal symptoms who are visiting the participating site, investigators will ensure that each candidate meets all the inclusion criteria and none of exclusion criteria. Suitable participants will be informed during the visit about the nature of the investigational study by receiving first information about the investigational product (food supplement) and invited to participate later when all questions have been addressed. A 14 days' period of reflexion is possible for every participant in accordance with Good Clinical Practice.
The procedures involved will be explained in detail and written consent must be obtained with subject and investigators signature before subject participation. The total duration of each participant in the study will be 16 weeks (12 weeks treatment + 4 weeks follow up). The participation in the study is completely voluntary.
The study consists of 4 visits: 3 visits until the end of treatment (EoT) with 1 follow up/end of study visit (FU/EoS) after treatment completion.
SE5-OH tablets will be administrated in tablets (4 per day) by daily oral intake until the day before the end of treatment date (week 12). Non-administrated SE5-OH tablets and VMS diary competition will be verified during the study in the corresponding visits until the EoS (visit 4).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Menopause
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Multicentre, exploratory, prospective, open-labelled study to evaluate the efficacy of SE5-OH tablets on menopausal symptoms in healthy women experiencing menopausal symptoms after 12 weeks of administration.
Primary Study Purpose
OTHER
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SE5-OH tablets
The product under investigation is a food supplement that contains SE5-OH (Fermented Soy germ, include S-equol), Crystalline cellulose, Oats fiber, Agar, Cyclic oligosaccharide, HPMC, Reduced syrup. The food supplement is presented in sealed bottles, each bottle contains 120 tablets with the recommended daily dose of 4 tablets per day administrated orally with a glass of water. The 4 tablets can be administrated together in a unique intake or in 2 separated intakes (2 tablets/intake) along the day.
Group Type
EXPERIMENTAL
SE5-OH tablets
Intervention Type
DIETARY_SUPPLEMENT
SE5-OH (Fermented Soy germ, include S-equol), Crystalline cellulose, Oats fiber, Agar, Cyclic oligosaccharide, HPMC, Reduced syrup.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SE5-OH tablets
SE5-OH (Fermented Soy germ, include S-equol), Crystalline cellulose, Oats fiber, Agar, Cyclic oligosaccharide, HPMC, Reduced syrup.
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 45-60 years healthy women who have provided signed ICF.
* Experiencing menopause symptoms for at least 1 month.
* Total MRS score ≥9 at inclusion time (baseline).
MRS with a score equal or above 9 include women with moderate to severe menopausal symptoms according to the validated analysis of this questionnaire.
* Experiencing menopause symptoms for at least 1 month.
* Total MRS score ≥9 at inclusion time (baseline).
MRS with a score equal or above 9 include women with moderate to severe menopausal symptoms according to the validated analysis of this questionnaire.
Exclusion Criteria
* Women currently receiving hormone replacement therapy (HRT) or bio identical hormone replacement therapy (BHRT) or have received HRT/BHRT in the last 3 months.
* Pregnant, nursing women or women planning to become pregnant\*.
* Subject with a history or presence of clinically severe disease such as hepatic, renal, endocrine, hematologic, immunologic (including chronic inflammatory conditions) and cancer disease.
* History or presence psychosomatic diseases (drug treatment), epilepsy, rheumatism.
* Allergies to soy.
* History of any food behaviour complication (lacking sufficient intake and/or over intake of food)
* Intestinal malabsorption that could decrease food supplements intestinal absorption.
* Receiving any drug during the last 3 months for menopause symptoms or any food supplement during the last 1 month that could decrease or hide/mask the effect of the experimental product.
* Participation to another clinical trial.
* Any other medical problem identified by the investigator that could alter the ability of the volunteer to participate to the study including non-treated/non controlled thyroid disease, diabetes (among others).
* A negative urine or serum pregnancy test (minimum sensitivity 25 IU/L or HCG equivalent units) must be performed prior to subject enrolment and must be negative 24 hours prior to initiation of study treatment in case of any suspicious.
* Pregnant, nursing women or women planning to become pregnant\*.
* Subject with a history or presence of clinically severe disease such as hepatic, renal, endocrine, hematologic, immunologic (including chronic inflammatory conditions) and cancer disease.
* History or presence psychosomatic diseases (drug treatment), epilepsy, rheumatism.
* Allergies to soy.
* History of any food behaviour complication (lacking sufficient intake and/or over intake of food)
* Intestinal malabsorption that could decrease food supplements intestinal absorption.
* Receiving any drug during the last 3 months for menopause symptoms or any food supplement during the last 1 month that could decrease or hide/mask the effect of the experimental product.
* Participation to another clinical trial.
* Any other medical problem identified by the investigator that could alter the ability of the volunteer to participate to the study including non-treated/non controlled thyroid disease, diabetes (among others).
* A negative urine or serum pregnancy test (minimum sensitivity 25 IU/L or HCG equivalent units) must be performed prior to subject enrolment and must be negative 24 hours prior to initiation of study treatment in case of any suspicious.
Minimum Eligible Age
45 Years
Maximum Eligible Age
60 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Adknoma Health Research
INDUSTRY
Sponsor Role
collaborator
Nutrition & Sante Iberia
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clínica Palacios Madrid
Madrid, Madrid, Spain
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Spain
References
Explore related publications, articles, or registry entries linked to this study.
Goodman NF, Cobin RH, Ginzburg SB, Katz IA, Woode DE; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause. Endocr Pract. 2011 Nov-Dec;17 Suppl 6:1-25. doi: 10.4158/ep.17.s6.1. No abstract available.
Reference Type
BACKGROUND
Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. Climacteric. 2014 Oct;17(5):557-63. doi: 10.3109/13697137.2014.946279. Epub 2014 Aug 25.
Reference Type
BACKGROUND
Brimacombe J, Berry A. The laryngeal mask airway for dental surgery--a review. Aust Dent J. 1995 Feb;40(1):10-4. doi: 10.1111/j.1834-7819.1995.tb05605.x.
Reference Type
BACKGROUND
Delamater L, Santoro N. Management of the Perimenopause. Clin Obstet Gynecol. 2018 Sep;61(3):419-432. doi: 10.1097/GRF.0000000000000389.
Reference Type
BACKGROUND
Avis NE, Stellato R, Crawford S, Bromberger J, Ganz P, Cain V, Kagawa-Singer M. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med. 2001 Feb;52(3):345-56. doi: 10.1016/s0277-9536(00)00147-7.
Reference Type
BACKGROUND
Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol. 1995 Nov;13(11):2737-44. doi: 10.1200/JCO.1995.13.11.2737.
Reference Type
BACKGROUND
Palacios S, Stevenson JC, Schaudig K, Lukasiewicz M, Graziottin A. Hormone therapy for first-line management of menopausal symptoms: Practical recommendations. Womens Health (Lond). 2019 Jan-Dec;15:1745506519864009. doi: 10.1177/1745506519864009.
Reference Type
BACKGROUND
Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017 Jan 17;1(1):CD004143. doi: 10.1002/14651858.CD004143.pub5.
Reference Type
BACKGROUND
Nappi RE, Kroll R, Siddiqui E, Stoykova B, Rea C, Gemmen E, Schultz NM. Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause. 2021 May 24;28(8):875-882. doi: 10.1097/GME.0000000000001793.
Reference Type
BACKGROUND
Krizova L, Dadakova K, Kasparovska J, Kasparovsky T. Isoflavones. Molecules. 2019 Mar 19;24(6):1076. doi: 10.3390/molecules24061076.
Reference Type
BACKGROUND
Setchell KD, Clerici C. Equol: history, chemistry, and formation. J Nutr. 2010 Jul;140(7):1355S-62S. doi: 10.3945/jn.109.119776. Epub 2010 Jun 2.
Reference Type
BACKGROUND
Mayo B, Vazquez L, Florez AB. Equol: A Bacterial Metabolite from The Daidzein Isoflavone and Its Presumed Beneficial Health Effects. Nutrients. 2019 Sep 16;11(9):2231. doi: 10.3390/nu11092231.
Reference Type
BACKGROUND
Weber MA, Limpens J, Roovers JP. Assessment of vaginal atrophy: a review. Int Urogynecol J. 2015 Jan;26(1):15-28. doi: 10.1007/s00192-014-2464-0. Epub 2014 Jul 22.
Reference Type
BACKGROUND
Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer. 2006;55(1):1-12. doi: 10.1207/s15327914nc5501_1.
Reference Type
BACKGROUND
Setchell KD, Clerici C, Lephart ED, Cole SJ, Heenan C, Castellani D, Wolfe BE, Nechemias-Zimmer L, Brown NM, Lund TD, Handa RJ, Heubi JE. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9. doi: 10.1093/ajcn/81.5.1072.
Reference Type
BACKGROUND
Khatoon A, Husain S, Husain S, Hussain S. An Overview of Menopausal Symptoms Using the Menopause Rating Scale in a Tertiary Care Center. J Midlife Health. 2018 Jul-Sep;9(3):150-154. doi: 10.4103/jmh.JMH_31_18.
Reference Type
BACKGROUND
Ahsan M, Mallick AK. The Effect of Soy Isoflavones on the Menopause Rating Scale Scoring in Perimenopausal and Postmenopausal Women: A Pilot Study. J Clin Diagn Res. 2017 Sep;11(9):FC13-FC16. doi: 10.7860/JCDR/2017/26034.10654. Epub 2017 Sep 1.
Reference Type
BACKGROUND
Erekson EA, Yip SO, Wedderburn TS, Martin DK, Li FY, Choi JN, Kenton KS, Fried TR. The Vulvovaginal Symptoms Questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women. Menopause. 2013 Sep;20(9):973-9. doi: 10.1097/GME.0b013e318282600b.
Reference Type
BACKGROUND
Fong TC, Ng SM. Measuring engagement at work: validation of the Chinese version of the Utrecht Work Engagement Scale. Int J Behav Med. 2012 Sep;19(3):391-7. doi: 10.1007/s12529-011-9173-6.
Reference Type
BACKGROUND
Alqurashi YD, Dawidziuk A, Alqarni A, Kelly J, Moss J, Polkey MI, Morrell MJ. A visual analog scale for the assessment of mild sleepiness in patients with obstructive sleep apnea and healthy participants. Ann Thorac Med. 2021 Apr-Jun;16(2):141-147. doi: 10.4103/atm.ATM_437_20. Epub 2021 Feb 19.
Reference Type
BACKGROUND
Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation. Obstet Gynecol Clin North Am. 2011 Sep;38(3):489-501. doi: 10.1016/j.ogc.2011.05.006.
Reference Type
BACKGROUND
Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, Sternfeld B, Matthews K. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health. 2006 Jul;96(7):1226-35. doi: 10.2105/AJPH.2005.066936. Epub 2006 May 30.
Reference Type
BACKGROUND
Nappi RE, Martini E, Cucinella L, Martella S, Tiranini L, Inzoli A, Brambilla E, Bosoni D, Cassani C, Gardella B. Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women. Front Endocrinol (Lausanne). 2019 Aug 21;10:561. doi: 10.3389/fendo.2019.00561. eCollection 2019.
Reference Type
BACKGROUND
Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines. The detection and management of vaginal atrophy. Number 145, May 2004. Int J Gynaecol Obstet. 2005 Feb;88(2):222-8. doi: 10.1016/j.ijgo.2004.11.003.
Reference Type
BACKGROUND
Sathyapalan T, Aye M, Rigby AS, Thatcher NJ, Dargham SR, Kilpatrick ES, Atkin SL. Soy isoflavones improve cardiovascular disease risk markers in women during the early menopause. Nutr Metab Cardiovasc Dis. 2018 Jul;28(7):691-697. doi: 10.1016/j.numecd.2018.03.007. Epub 2018 Apr 10.
Reference Type
BACKGROUND
Linderman GC, Lu J, Lu Y, Sun X, Xu W, Nasir K, Schulz W, Jiang L, Krumholz HM. Association of Body Mass Index With Blood Pressure Among 1.7 Million Chinese Adults. JAMA Netw Open. 2018 Aug 3;1(4):e181271. doi: 10.1001/jamanetworkopen.2018.1271.
Reference Type
BACKGROUND
Taku K, Melby MK, Kronenberg F, Kurzer MS, Messina M. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. Menopause. 2012 Jul;19(7):776-90. doi: 10.1097/gme.0b013e3182410159.
Reference Type
BACKGROUND
Colacurci N, De Franciscis P, Atlante M, Mancino P, Monti M, Volpini G, Benvenuti C. Endometrial, breast and liver safety of soy isoflavones plus Lactobacillus sporogenes in post-menopausal women. Gynecol Endocrinol. 2013 Mar;29(3):209-12. doi: 10.3109/09513590.2012.738724. Epub 2012 Nov 30.
Reference Type
BACKGROUND
Alekel DL, Genschel U, Koehler KJ, Hofmann H, Van Loan MD, Beer BS, Hanson LN, Peterson CT, Kurzer MS. Soy Isoflavones for Reducing Bone Loss Study: effects of a 3-year trial on hormones, adverse events, and endometrial thickness in postmenopausal women. Menopause. 2015 Feb;22(2):185-97. doi: 10.1097/GME.0000000000000280.
Reference Type
BACKGROUND
Nahas EA, Nahas-Neto J, Orsatti FL, Carvalho EP, Oliveira ML, Dias R. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study. Maturitas. 2007 Nov 20;58(3):249-58. doi: 10.1016/j.maturitas.2007.08.012. Epub 2007 Oct 29.
Reference Type
BACKGROUND
Palacios S, Pornel B, Vazquez F, Aubert L, Chantre P, Mares P. Long-term endometrial and breast safety of a specific, standardized soy extract. Climacteric. 2010 Aug;13(4):368-75. doi: 10.3109/13697131003660585.
Reference Type
BACKGROUND
Messina M. The endometrial effects of isoflavones: a discussion paper. Complement Ther Clin Pract. 2008 Aug;14(3):212-4. doi: 10.1016/j.ctcp.2008.04.005. Epub 2008 Jun 20. No abstract available.
Reference Type
BACKGROUND
Hooper L, Madhavan G, Tice JA, Leinster SJ, Cassidy A. Effects of isoflavones on breast density in pre- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trials. Hum Reprod Update. 2010 Nov-Dec;16(6):745-60. doi: 10.1093/humupd/dmq011. Epub 2010 May 28.
Reference Type
BACKGROUND
Huser S, Guth S, Joost HG, Soukup ST, Kohrle J, Kreienbrock L, Diel P, Lachenmeier DW, Eisenbrand G, Vollmer G, Nothlings U, Marko D, Mally A, Grune T, Lehmann L, Steinberg P, Kulling SE. Effects of isoflavones on breast tissue and the thyroid hormone system in humans: a comprehensive safety evaluation. Arch Toxicol. 2018 Sep;92(9):2703-2748. doi: 10.1007/s00204-018-2279-8. Epub 2018 Aug 21.
Reference Type
BACKGROUND
Utian WH, Jones M, Setchell KD. S-equol: a potential nonhormonal agent for menopause-related symptom relief. J Womens Health (Larchmt). 2015 Mar;24(3):200-8. doi: 10.1089/jwh.2014.5006. Epub 2015 Feb 18.
Reference Type
BACKGROUND
Kim IS. Current Perspectives on the Beneficial Effects of Soybean Isoflavones and Their Metabolites for Humans. Antioxidants (Basel). 2021 Jun 30;10(7):1064. doi: 10.3390/antiox10071064.
Reference Type
BACKGROUND
Ishiwata N, Melby MK, Mizuno S, Watanabe S. New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women. Menopause. 2009 Jan-Feb;16(1):141-8. doi: 10.1097/gme.0b013e31818379fa.
Reference Type
BACKGROUND
Aso T. Equol improves menopausal symptoms in Japanese women. J Nutr. 2010 Jul;140(7):1386S-9S. doi: 10.3945/jn.109.118307. Epub 2010 May 19.
Reference Type
BACKGROUND
Aso T, Uchiyama S, Matsumura Y, Taguchi M, Nozaki M, Takamatsu K, Ishizuka B, Kubota T, Mizunuma H, Ohta H. A natural S-equol supplement alleviates hot flushes and other menopausal symptoms in equol nonproducing postmenopausal Japanese women. J Womens Health (Larchmt). 2012 Jan;21(1):92-100. doi: 10.1089/jwh.2011.2753. Epub 2011 Oct 12.
Reference Type
BACKGROUND
Jenks BH, Iwashita S, Nakagawa Y, Ragland K, Lee J, Carson WH, Ueno T, Uchiyama S. A pilot study on the effects of S-equol compared to soy isoflavones on menopausal hot flash frequency. J Womens Health (Larchmt). 2012 Jun;21(6):674-82. doi: 10.1089/jwh.2011.3153. Epub 2012 Mar 12.
Reference Type
BACKGROUND
Setchell KD, Cole SJ. Method of defining equol-producer status and its frequency among vegetarians. J Nutr. 2006 Aug;136(8):2188-93. doi: 10.1093/jn/136.8.2188.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EQUELLE_22_01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Estromineral Serena Plus and Symptomatic Menopause
NCT01730989
UNKNOWN
NA
Effects of Menopause Hormonal Therapy and Selective Serotonin Reuptake Inhibitor on Cognition, Sexual Function and Quality of Life
NCT05050981
COMPLETED
A Study to Learn More About the Menopausal Hormone Therapies in Korea
NCT06033521
COMPLETED
12-week Multi-vitamin/Mineral Supplementation on Peri-menopause Symptoms, Cognition, Sleep, and Psychological Well-being.
NCT07242430
NOT_YET_RECRUITING
NA
Impact of a Probiotic Combination on Quality of Life and Symptoms in Peri- and Postmenopausal Women
NCT06604234
COMPLETED
NA
Isoflavones and Magnolia Extract in the Quality of Life in Menopausal Women
NCT01805674
COMPLETED
Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients
NCT00962585
COMPLETED
PHASE2
Symptom Monitoring and Menopausal Symptoms
NCT05603234
COMPLETED
NA
Diet, Cardiometabolic Risk (CM) and Menopause Symptoms
NCT05764473
COMPLETED
NA
Study to Investigate the Effectiveness of a Food Supplement Made of Hop in the Improvement of Menopausal Symptoms
NCT03875430
UNKNOWN
4-week Seaweed Supplementation on Menopause Symptoms and Psychological Wellbeing
NCT05759936
COMPLETED
NA
Effects of Black Cohosh on Menopausal Hot Flashes
NCT00010712
COMPLETED
PHASE2
MENOS@Work Trial: A Self-help CBT Intervention for Working Women
NCT02623374
COMPLETED
NA
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
NCT06186531
RECRUITING
PHASE2
A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause
NCT05033886
COMPLETED
PHASE3
FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms
NCT05312567
COMPLETED
PHASE2
Observational Study to Evaluate the Quality of Life of Healthy Postmenopausal Women Who Take Coenzyme Q-Ubiquinol
NCT03429231
COMPLETED
Metabotyping in the Postmenopausal Stage
NCT05397015
COMPLETED
Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
NCT06057896
COMPLETED
Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause
NCT07118891
RECRUITING
PHASE1/PHASE2
Alternative Therapies for Menopause: A Randomized Trial
NCT00061711
COMPLETED
NA
Citalopram in Treating Postmenopausal Women With Hot Flashes
NCT00363909
COMPLETED
PHASE3
Menopausal Vaginal Microbiome
NCT05122065
UNKNOWN
Efficacy of CL25216 on Vasomotor Symptoms in Women During Perimenopause
NCT07112651
RECRUITING
NA
12-week Magnesium Supplementation on Peri-menopause Symptoms, Cognition, Sleep, and Psychological Well-being
NCT07235878
NOT_YET_RECRUITING
NA